According to a new report from EP Vantage, despite a surge in R&D productivity during the past couple of years, the situation might see a dramatic change this year. The rush of drugs that have hit the market and rapidly gone on to achieve blockbuster status has certainly driven investor confidence and share price valuations. Read More
As we enter the final trading week of February, public biotech companies are maintaining their relentless performance on the capital markets. The BioWorld Blue Chip Index, for example, is up almost 20 percent in value since the start of the new year. The price-weighted index that includes many of the industry’s leading biotechnology companies outperformed the Dow Jones Industrial average, which recorded a 3 percent drop and the Nasdaq Composite index, which was up 2 percent in the same period. Read More